1. 14 POST-HOC ANALYSIS OF TOFACITINIB CROHN'S DISEASE PHASE 2 INDUCTION EFFICACY IN SUBGROUPS WITH BASELINE ENDOSCOPIC OR BIOMARKER EVIDENCE OF INFLAMMATION. (18th January 2018) Authors: Sands, Bruce E; Panés, Julian; Higgins, Peter D R; Moscariello, Michele; Chan, Gary; Su, Chinyu; Wang, Wenjin; Maller, Eric Journal: Inflammatory bowel diseases Issue: Volume 24(2018)Supplement 1 Page Start: S56 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials. Issue 11 (6th October 2021) Authors: Feagan, Brian G.; Khanna, Reena; Sandborn, William J.; Vermeire, Séverine; Reinisch, Walter; Su, Chinyu; Salese, Leonardo; Fan, Haiyun; Paulissen, Jerome; Woodworth, Deborah A.; Niezychowski, Wojciech; Sands, Bruce E. Journal: Alimentary pharmacology & therapeutics Issue: Volume 54:Issue 11/12(2021) Page Start: 1442 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Bridging Efficacy of Tofacitinib Immediate‐Release to Extended‐Release Formulations for Treatment of Ulcerative Colitis: Application of a Model‐Informed Drug Development Approach. Issue 8 (13th May 2022) Authors: Mukherjee, Arnab; Tsuchiwata, Shinichi; Chang, Cheng; Nicholas, Timothy; Su, Chinyu; Le, Vu H.; Kushner, Joseph; Kulisek, Nicole Journal: Clinical pharmacology in drug development Issue: Volume 11:Issue 8(2022) Page Start: 976 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. Issue 2 (29th October 2019) Authors: Sands, Bruce E.; Armuzzi, Alessandro; Marshall, John K.; Lindsay, James O.; Sandborn, William J.; Danese, Silvio; Panés, Julián; Bressler, Brian; Colombel, Jean‐Frédéric; Lawendy, Nervin; Maller, Eric; Zhang, Haiying; Chan, Gary; Salese, Leonardo; Tsilkos, Konstantinos; Marren, Amy; Su, Chinyu Journal: Alimentary pharmacology & therapeutics Issue: Volume 51:Issue 2(2020) Page Start: 271 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical Trials. (21st April 2021) Authors: Panés, Julian; Vermeire, Séverine; Dubinsky, Marla C; Loftus, Edward V; Lawendy, Nervin; Wang, Wenjin; Salese, Leonardo; Su, Chinyu; Modesto, Irene; Guo, Xiang; Colombel, Jean-Frederic Journal: Journal of Crohn's and colitis Issue: Volume 15:Number 11(2021) Page Start: 1852 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Efficacy of Tofacitinib in Patients With Ulcerative Colitis by Prior Tumor Necrosis Factor Inhibitor Treatment Status: Results From OCTAVE Induction and Maintenance Studies: 640. (October 2017) Authors: Dubinsky, Marla C.; Peyrin‐Biroulet, Laurent; Melmed, Gil Y.; Hou, Jason K.; Woodworth, Deborah A.; Friedman, Gary S.; Zhang, Haiying; Maller, Eric; Quirk, Daniel; Nduaka, Chudy I.; Su, Chinyu Journal: American journal of gastroenterology Issue: Volume 112(2017)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Exposure‐Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies. Issue 1 (27th April 2022) Authors: Mukherjee, Arnab; Tsuchiwata, Shinichi; Nicholas, Timothy; Cook, Jack A.; Modesto, Irene; Su, Chinyu; D'Haens, Geert R.; Sandborn, William J. Journal: Clinical pharmacology & therapeutics Issue: Volume 112:Issue 1(2022) Page Start: 90 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Exposure–response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose‐ranging phase 2 trial. (23rd March 2018) Authors: Mukherjee, Arnab; Hazra, Anasuya; Smith, Mike K.; Martin, Steven W.; Mould, Diane R.; Su, Chinyu; Niezychowski, Wojciech Journal: British journal of clinical pharmacology Issue: Volume 84:Number 6(2018:Dec.) Page Start: 1136 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Fecal Calprotectin Levels, C‐Reactive Protein Levels, and Partial Mayo Score as Early Predictors of Clinical and Endoscopic Outcomes in Patients With Ulcerative Colitis Treated With Tofacitinib in a Phase 2 Study: 823. (October 2019) Authors: Dubinsky, Marla C.; Hudesman, David P.; Kulisek, Nicole; Salese, Leonardo; Paulissen, Jerome; Su, Chinyu; Magro, Fernando Journal: American journal of gastroenterology Issue: Volume 114 (2019)ACG Abstracts 1:Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib. Issue 10 (15th September 2018) Authors: Winthrop, Kevin L; Melmed, Gil Y; Vermeire, Séverine; Long, Millie D; Chan, Gary; Pedersen, Ronald D; Lawendy, Nervin; Thorpe, Andrew J; Nduaka, Chudy I; Su, Chinyu Journal: Inflammatory bowel diseases Issue: Volume 24:Issue 10(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗